2/23
07:33 am
aclx
Stocks making the biggest moves premarket: Arcellx, Novo Nordisk, Domino's Pizza and more [CNBC]
Neutral
Report
Stocks making the biggest moves premarket: Arcellx, Novo Nordisk, Domino's Pizza and more [CNBC]
2/23
07:09 am
aclx
ACLX Stock Alert: Halper Sadeh LLC is Investigating Whether Arcellx, Inc. is Obtaining a Fair Price for its Shareholders
Low
Report
ACLX Stock Alert: Halper Sadeh LLC is Investigating Whether Arcellx, Inc. is Obtaining a Fair Price for its Shareholders
2/23
06:23 am
aclx
Gilead to acquire Arcellx for $7.8 billion [Yahoo! Finance]
Low
Report
Gilead to acquire Arcellx for $7.8 billion [Yahoo! Finance]
2/23
06:01 am
aclx
Gilead Sciences to Acquire Arcellx to Maximize Long-term Potential of Anito-cel
High
Report
Gilead Sciences to Acquire Arcellx to Maximize Long-term Potential of Anito-cel
2/18
10:42 pm
aclx
Assessing Arcellx (ACLX) Valuation After New Anito Cel Safety Data And Shifting Analyst Views [Yahoo! Finance]
Medium
Report
Assessing Arcellx (ACLX) Valuation After New Anito Cel Safety Data And Shifting Analyst Views [Yahoo! Finance]
2/16
12:38 pm
aclx
Arcellx (ACLX) Shares Encouraging Data on Latest Laboratory Study [Yahoo! Finance]
Low
Report
Arcellx (ACLX) Shares Encouraging Data on Latest Laboratory Study [Yahoo! Finance]
2/12
07:55 am
aclx
Arcellx (NASDAQ:ACLX) was downgraded by analysts at Rothschild & Co Redburn from a "buy" rating to a "neutral" rating. They now have a $82.00 price target on the stock.
Low
Report
Arcellx (NASDAQ:ACLX) was downgraded by analysts at Rothschild & Co Redburn from a "buy" rating to a "neutral" rating. They now have a $82.00 price target on the stock.
2/6
08:42 am
aclx
Arcellx (ACLX) Declined Despite Positive Clinical Trial Results [Yahoo! Finance]
Low
Report
Arcellx (ACLX) Declined Despite Positive Clinical Trial Results [Yahoo! Finance]
2/5
08:04 am
aclx
Arcellx (NASDAQ:ACLX) had its "buy" rating reaffirmed by analysts at Needham & Company LLC. They now have a $105.00 price target on the stock.
Medium
Report
Arcellx (NASDAQ:ACLX) had its "buy" rating reaffirmed by analysts at Needham & Company LLC. They now have a $105.00 price target on the stock.
2/4
01:16 pm
aclx
Arcellx (NASDAQ:ACLX) had its "buy" rating reaffirmed by analysts at HC Wainwright. They now have a $115.00 price target on the stock.
Low
Report
Arcellx (NASDAQ:ACLX) had its "buy" rating reaffirmed by analysts at HC Wainwright. They now have a $115.00 price target on the stock.
2/4
09:00 am
aclx
Arcellx Announces Late-Breaking Presentation at TANDEM Demonstrating Unique, High Target-Specificity of anito-cel’s D-Domain Binder
Low
Report
Arcellx Announces Late-Breaking Presentation at TANDEM Demonstrating Unique, High Target-Specificity of anito-cel’s D-Domain Binder
2/3
01:41 am
aclx
Assessing Arcellx (ACLX) Valuation After Recent Share Price Swings And Conflicting P/B And DCF Signals [Yahoo! Finance]
Low
Report
Assessing Arcellx (ACLX) Valuation After Recent Share Price Swings And Conflicting P/B And DCF Signals [Yahoo! Finance]
2/2
10:40 pm
aclx
Is Arcellx (ACLX) Still Attractively Priced After Strong Multi Year Share Price Gains [Yahoo! Finance]
Low
Report
Is Arcellx (ACLX) Still Attractively Priced After Strong Multi Year Share Price Gains [Yahoo! Finance]
1/31
10:17 pm
aclx
Arcellx Director Sells 6,000 Shares for $450,000 [Yahoo! Finance]
Low
Report
Arcellx Director Sells 6,000 Shares for $450,000 [Yahoo! Finance]
1/30
12:53 am
aclx
UBS Initiates Coverage of Arcellx With Bullish Outlook as Biotech Fundamentals Inflect [Yahoo! Finance]
Low
Report
UBS Initiates Coverage of Arcellx With Bullish Outlook as Biotech Fundamentals Inflect [Yahoo! Finance]
1/23
05:06 am
aclx
Arcellx (NASDAQ:ACLX) had its "sell (d-)" rating reaffirmed by analysts at
Weiss Ratings.
Low
Report
Arcellx (NASDAQ:ACLX) had its "sell (d-)" rating reaffirmed by analysts at
Weiss Ratings.
1/21
04:14 pm
aclx
Arcellx to Advance the Conversation on Its Platform and the Importance of Early CAR T Access for Patients with Multiple Myeloma During the 2026 Tandem Meetings [Yahoo! Finance]
Low
Report
Arcellx to Advance the Conversation on Its Platform and the Importance of Early CAR T Access for Patients with Multiple Myeloma During the 2026 Tandem Meetings [Yahoo! Finance]
1/21
04:00 pm
aclx
Arcellx to Advance the Conversation on Its Platform and the Importance of Early CAR T Access for Patients with Multiple Myeloma During the 2026 Tandem Meetings
Low
Report
Arcellx to Advance the Conversation on Its Platform and the Importance of Early CAR T Access for Patients with Multiple Myeloma During the 2026 Tandem Meetings
1/7
10:02 am
aclx
Arcellx (NASDAQ:ACLX) is now covered by analysts at UBS Group AG. They set a "buy" rating on the stock.
Medium
Report
Arcellx (NASDAQ:ACLX) is now covered by analysts at UBS Group AG. They set a "buy" rating on the stock.
1/7
04:06 am
aclx
Arcellx (NASDAQ:ACLX) was given a new $100.00 price target on by analysts at UBS Group AG.
Medium
Report
Arcellx (NASDAQ:ACLX) was given a new $100.00 price target on by analysts at UBS Group AG.
12/24
07:01 pm
aclx
Arcellx (ACLX) Valuation Check After Wells Fargo Launches Coverage on Its Multiple Myeloma CAR-T Program [Yahoo! Finance]
Low
Report
Arcellx (ACLX) Valuation Check After Wells Fargo Launches Coverage on Its Multiple Myeloma CAR-T Program [Yahoo! Finance]
12/24
06:15 am
aclx
Arcellx (NASDAQ:ACLX) was upgraded by analysts at Wells Fargo & Company to a "strong-buy" rating.
Low
Report
Arcellx (NASDAQ:ACLX) was upgraded by analysts at Wells Fargo & Company to a "strong-buy" rating.
12/22
05:01 am
aclx
Arcellx (NASDAQ:ACLX) is now covered by analysts at Wells Fargo & Company. They set an "overweight" rating on the stock.
Low
Report
Arcellx (NASDAQ:ACLX) is now covered by analysts at Wells Fargo & Company. They set an "overweight" rating on the stock.
12/17
08:24 am
aclx
Arcellx: Funded Into 2028 With Strong Clinical Data [Seeking Alpha]
Low
Report
Arcellx: Funded Into 2028 With Strong Clinical Data [Seeking Alpha]
12/8
01:20 pm
aclx
Arcellx (NASDAQ:ACLX) had its "buy" rating reaffirmed by analysts at Canaccord Genuity Group Inc.. They now have a $130.00 price target on the stock.
Medium
Report
Arcellx (NASDAQ:ACLX) had its "buy" rating reaffirmed by analysts at Canaccord Genuity Group Inc.. They now have a $130.00 price target on the stock.